Reconsidering the rVSVΔG-ZEBOV-GP vaccine during the 2026 Bundibugyo virus outbreak

The Lancet Infectious Diseases·July 20

Infectious Diseases Bundibugyo Virus Disease Ebola Virus Disease Live Recombinant Vesicular Stomatitis Virus Vaccine Ervebo RVSVΔG-ZEBOV-GP

Summary

View source

What was studied

The paper reconsiders the use of the rVSVΔG-ZEBOV-GP vaccine (licensed for Ebola virus disease caused by Zaire ebolavirus) during a 2026 outbreak of Bundibugyo virus (BDBV), a distinct Ebolavirus species.

Caveats

No sample size, key results, limitations, or practice takeaway could be determined from the available metadata alone.
Study design is assumed to be a commentary or opinion piece based on the title framing ('Reconsidering...'); this cannot be confirmed without full text.
The paper's full text was not provided — only bibliographic metadata is available. All structured outputs are based solely on the title, journal, and DOI; no specific findings, population data, or conclusions can be extracted.

Reconsidering the rVSVΔG-ZEBOV-GP vaccine during the 2026 Bundibugyo virus outbreak

Summary

What was studied

Caveats

Related Questions

Reconsidering the rVSVΔG-ZEBOV-GP vaccine during the 2026 Bundibugyo virus outbreak

Summary

What was studied

Caveats

Related Questions